-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Fgt0Cow9UxvWE7LNkfPvFci+TNFuSMqBAiJmP23foJlxp46ImO1MIz1CQiXz2sYG 6LhWifikkqyiR7lGFNauBg== 0001144204-09-030701.txt : 20090603 0001144204-09-030701.hdr.sgml : 20090603 20090603123047 ACCESSION NUMBER: 0001144204-09-030701 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20090602 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20090603 DATE AS OF CHANGE: 20090603 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Forticell BioScience, Inc. CENTRAL INDEX KEY: 0000889992 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 113068704 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-27368 FILM NUMBER: 09870517 BUSINESS ADDRESS: STREET 1: 3960 BROADWAY STREET 2: BLDG 28 CITY: NEW YORK STATE: NY ZIP: 10032 BUSINESS PHONE: (212) 740-6999 MAIL ADDRESS: STREET 1: 3960 BROADWAY, CITY: NEW YORK STATE: NY ZIP: 10032 FORMER COMPANY: FORMER CONFORMED NAME: ORTEC INTERNATIONAL INC DATE OF NAME CHANGE: 19950822 8-K 1 v151466_8k.htm Unassociated Document
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
_____________________
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): June 2, 2009
 
Forticell Bioscience, Inc.
(Exact Name of Registrant as Specified in its Charter)
 
DE
0-27368
11-3068704
(State or other Jurisdiction
of Incorporation)
(Commission File Number)
(I.R.S. Employer
Identification No.)
 
3960 Broadway
New York, NY
10032
(Address of Principal Executive Offices)
(Zip Code)
 
Registrant's telephone number, including area code: (646) 218-1885
 
(Former name or former address, if changed from last report)
 
_____________________
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
|_|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
|_|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
|_|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
|_|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 

Item 7.01 Regulation FD Disclosure.
 
On June 2, 2009, we timely filed our response to the Food & Drug Administration’s April 2008 letter to us regarding deficiencies they believe existed in our pre-market approval application for the use of cryopreserved ORCEL in the treatment of venous leg ulcers.
 
 
 
 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Forticell Bioscience, Inc.
(Registrant)
 
Date: June 3, 2009
By:
/s/ Alan W. Schoenbart
   
Chief Executive Officer

 
 
 

-----END PRIVACY-ENHANCED MESSAGE-----